

**Remarks**

Claims 1-33 are pending.

Claims 1 and 3 are amended.

Claims 4, 5, 6, 7, 11, 12, and claims 13-32 (the claims of Group II) have been withdrawn.

Support for claim 1 is found in claim 3 and support for claim 3 is found in paragraph 12 of the application as filed.

The genus and species claim elections have been made, as above.

The applicant traverses the genus election of Group I, and asserts that the methods of claim 1 and claim 13 share a linking special technical feature, because each requires the steps of exposing a cell to a compound and determining the change in gene expression of one or more genes in response to the exposure. In claim 1 (Group I) the exposed thing is merely described as a "cell" and the compound is called a "test compound". In claim 13 (Group II) the thing exposed is referred to as "a subject" and the compound is called a "therapeutic compound". Despite the different nomenclatures, the principle is the same. The methods of Groups I and II are intended for different purposes - one to screen for anti-neoplastic activity and the other to monitoring the efficacy of a prophylactic treatment, but the two methods could reasonably be said to share a linking special technical feature.

No new matter has been added and the genes selected are all found in Table 1.

The applicant does not traverse the restrictions.

Applicants respectfully request entry of the present amendment.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'A. Bell', enclosed within a hand-drawn oval.

Adam Warwick Bell, BSc. DPhil. JD. (USPTO No. 43,490)

BELL & ASSOCIATES

58 West Portal Avenue # 121

San Francisco, California 94127

Tel: (415) 752-4085. Fax: (415) 276-6040

[info@bell-iplaw.com](mailto:info@bell-iplaw.com)